Photocatalytic synthesis achieves enantioselective outcomes in chiral compounds, suggesting improvements in drug development.
A photocatalytic asymmetric protocol for the synthesis of chiral dihydroisoquinolone scaffolds, which are prevalent in natural products and pharmaceuticals, has been developed. Utilizing chiral C₂-symmetric arylthiol as an H atom transfer catalyst, the enantioselective hydroamination-cyclization provides efficient access to a wide range of valuable 4-substituted 3,4-dihydroisoquinolones with moderate to high regio- and enantioselectivity. The synthetic utility of this methodology is demonstrated by the formal synthesis of several bioactive alkaloid intermediates.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: